58 results on '"SORIANO, Alessandra"'
Search Results
2. Proof-of-Concept Human Organ-on-Chip Study: First Step of Platform to Assess Neuro-Immunological Communication Involved in Inflammatory Bowel Diseases.
- Author
-
Gabriel-Segard, Tristan, Rontard, Jessica, Miny, Louise, Dubuisson, Louise, Batut, Aurélie, Debis, Delphine, Gleyzes, Mélanie, François, Fabien, Larramendy, Florian, Soriano, Alessandra, Honegger, Thibault, and Paul, Stéphane
- Subjects
INFLAMMATORY bowel diseases ,DENDRITIC cells ,PROOF of concept ,NEUROLOGICAL disorders ,HUMAN experimentation ,GASTROINTESTINAL system ,DEEP brain stimulation - Abstract
Inflammatory bowel diseases (IBD) are complex chronic inflammatory disorders of the gastrointestinal (GI) tract. Recent evidence suggests that the gut-brain axis may be pivotal in gastrointestinal and neurological diseases, especially IBD. Here, we present the first proof of concept for a microfluidic technology to model bilateral neuro-immunological communication. We designed a device composed of three compartments with an asymmetric channel that allows the isolation of soma and neurites thanks to microchannels and creates an in vitro synaptic compartment. Human-induced pluripotent stem cell-derived cortical glutamatergic neurons were maintained in soma compartments for up to 21 days. We performed a localized addition of dendritic cells (MoDCs) to either the soma or synaptic compartment. The microfluidic device was coupled with microelectrode arrays (MEAs) to assess the impact on the electrophysiological activity of neurons while adding dendritic cells. Our data highlight that an electrophysiologic signal is transmitted between two compartments of glutamatergic neurons linked by synapses in a bottom-up way when soma is exposed to primed dendritic cells. In conclusion, our study authenticates communication between dendritic cells and neurons in inflammatory conditions such as IBD. This platform opens the way to complexification with gut components to reach a device for pharmacological compound screening by blocking the gut-brain axis at a mucosal level and may help patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10 ® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies.
- Author
-
Berger, Anne Emmanuelle, Gleizes, Aude, Waeckel, Louis, Roblin, Xavier, Krzysiek, Roman, Hacein-Bey-Abina, Salima, Soriano, Alessandra, and Paul, Stephane
- Subjects
ADALIMUMAB ,CHEMILUMINESCENCE immunoassay ,IMMUNOGLOBULINS ,INFLIXIMAB ,BIOLOGICAL monitoring ,DRUG dosage - Abstract
Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in gastroenterology. A new chemiluminescent instrument (i-TRACK
10® from Theradiag) could replace ELISA techniques to calculate the dosage of drugs and anti-drug antibodies. In this bi-centric study, we explored the analytical performances of i-TRACK10® using manual or automated (DS2® ) ELISA Lisa-Tracker® assays, and compared the results. Patients and methods. Intra- and inter-run performances were evaluated with i-TRACK10® in two different laboratories and for two different ranges of values for infliximab, adalimumab, and their respective antibodies. Patients' samples were used in the labs to compare the results obtained between the new instrument and either the manual Lisa-Tracker® or the automated DS2. Results. Intra- and inter-run performances were satisfactory, with values between 1.8% and 16.1% (for inter-run imprecision at low/medium values of infliximab). Results were generally comparable between assays. with the lowest value of correlation at 0.59 (anti-adalimumab dosage between i-TRACK10® and manual ELISA). Most often, values of drugs and anti-drug antibodies were higher with i-TRACK10® than with manual ELISA assay, and correlation values were better with automated ELISA. Agreements were globally acceptable, and the lowest coefficients of 0.7 was obtained for adalimumab values between i-TRACK10® and the two ELISA methods, and for anti-adalimumab values between i-TRACK10® and manual ELISA. The type of assay can potentially induce a change in the class of patients and lead to divergent therapeutic decisions. Conclusions. The new random-access instrument i-TRACK10® presents many advantages in a routine laboratory: rapidity, the possibility of standardization, usability, and expansion of the measurement range. Despite the relatively good agreement of results, it is preferable to use the same assay in longitudinal follow-up of a patient, because quantitative results were not completely equivalent especially for anti-drug antibodies. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Management of colovesical fistula: a systematic review.
- Author
-
ZIZZO, Maurizio, TUMIATI, David, BASSI, Maria C., ZANELLI, Magda, SANGUEDOLCE, Francesca, PORPIGLIA, Francesco, FIORI, Cristian, CAMPOBASSO, Davide, CASTRO RUIZ, Carolina, BERGAMASCHI, Franco A., MAESTRONI, Umberto V., CARRIERI, Giuseppe, CORMIO, Luigi, BIOLCHINI, Federico, PALI CELLI, Andrea, SORIANO, Alessandra, SASSATELLI, Romano, ASCANI, Stefano, ANNESSI, Valerio, and GIUNTA, Alessandro
- Published
- 2022
- Full Text
- View/download PDF
5. Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach.
- Author
-
Zanelli, Magda, Palicelli, Andrea, Sanguedolce, Francesca, Zizzo, Maurizio, Filosa, Alessandra, Ricci, Linda, Cresta, Camilla, Martino, Giovanni, Bisagni, Alessandra, Zanetti, Eleonora, di Donato, Francesco, Melli, Beatrice, Soriano, Alessandra, Cimino, Luca, Cavazza, Alberto, Vivian, Lisa Francesca, and Ascani, Stefano
- Subjects
PLASMA cell diseases ,HEMATOLOGY ,LYMPHOMAS ,PATHOLOGISTS ,BOLEN test - Abstract
Neoplasms with plasma cell differentiation may occasionally involve the skin. Cutaneous lesions may represent the first sign of an underlying systemic plasma cell malignancy, such as multiple myeloma, or the skin itself may be the primary site of occurrence of a hematological tumor with plasma cell differentiation. Starting from examples encountered in our daily practice, we discussed the diagnostic approach pathologists and clinicians should use when faced with cutaneous lesions with plasma cell differentiation. Cases of primary cutaneous marginal zone lymphoma, localized primary amyloidosis/amyloidoma, and cutaneous manifestations (secondary either to multiple myeloma or to plasmablastic lymphoma) are discussed, focusing on the importance of the adequate patient's work-up and precise clinicopathological correlation to get to the correct diagnosis and appropriate treatment. The pertinent literature has been reviewed, and the clinical presentation, pathological findings, main differential diagnoses, treatment, and outcome of neoplasms with plasma cell differentiation involving the skin are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. SARS-CoV-2-related lung pathology: macroscopic and histologic features and their clinical implications.
- Author
-
SANGUEDOLCE, Francesca, ZANELLI, Magda, ASCANI, Stefano, ZIZZO, Maurizio, TORTORELLA, Simona, SORIANO, Alessandra, CAVAZZA, Alberto, SOLLITTO, Francesco, and LOIZZI, Domenico
- Published
- 2022
- Full Text
- View/download PDF
7. Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.
- Author
-
Zanelli, Magda, Sanguedolce, Francesca, Zizzo, Maurizio, Palicelli, Andrea, Pellegrini, David, Farinacci, Sabrina, Soriano, Alessandra, Froio, Elisabetta, Cormio, Luigi, Carrieri, Giuseppe, Cavazza, Alberto, Merli, Francesco, Pileri, Stefano A., and Ascani, Stefano
- Subjects
LYMPHOMA diagnosis ,BLADDER tumors ,BIOPSY ,B cell lymphoma ,DIFFERENTIAL diagnosis ,RARE diseases - Abstract
Diffuse large B-cell lymphoma (DLBCL) represents the most frequent type of non-Hodgkin lymphoma. Globally, DLBCL is an aggressive disease, requiring an accurate diagnosis and prompt treatment. The diagnosis is often made on biopsy samples of a nodal mass, however, approximately 40% of DLBCL cases arise at extranodal sites. The most common extranodal site is the gastrointestinal tract, however any extranodal area may be primarily involved. Primary urinary bladder lymphoma represents only 0.2% of extranodal non-Hodgkin lymphomas, whereas secondary involvement of the urinary bladder by a systemic lymphoma is a more common event. Despite being rare, DLBCL is considered to represent the predominant primary urinary bladder lymphoma. The majority of cases reported in the bladder belong to the DLBCL, NOS group, and there are only rare cases of EBV-positive DLBCL, NOS. In this review, we summarize the current knowledge on DLBCL primarily occurring in the urinary bladder, with the aim of increasing clinician and pathologist awareness on this aggressive lymphoma rarely arising in the urinary bladder. Additionally, we focus on those entities which should be taken into consideration in the differential diagnosis, highlighting potential diagnostic pitfalls. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.
- Author
-
Gaggiano, Carla, Rigante, Donato, Hernández-Rodríguez, José, Vitale, Antonio, Tarsia, Maria, Soriano, Alessandra, Lopalco, Giuseppe, Iannone, Florenzo, Abdel Jaber, Masen, Giacomelli, Roberto, Wiȩsik-Szewczyk, Ewa, Cattalini, Marco, Frassi, Micol, Piga, Matteo, Ragab, Gaafar, Sota, Jurgen, Zunica, Fiammetta, Floris, Alberto, Sabato, Vito, and Hegazy, Mohamed Tharwat
- Abstract
Background: This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition. Methods: Clinical data of patients treated with ANA or CAN for recurrent inflammatory attacks due to the presence of the R92Q variant were retrospectively collected and analysed. Results: Data about 20 treatment courses with IL-1 inhibitors (16 with ANA and 4 with CAN) from 19 patients were collected. Mean age at disease onset was 20.2 ± 14.8 years. In 5 cases (26%) the R92Q variant was found in a family member affected by recurrent fever. The therapeutic response was complete in 13(68%) and partial in 2 patients (11%); treatment failure was observed in 4 cases (21%). Median AIDAI decreased from 10 (interquartile range [IQR] = 28) to 0 (IQR = 1) at the 12-month follow-up visit (p < 0.001). Mean ESR and median CRP dropped respectively from 40.8 ± 24.8 to 9.1 ± 4.5 mm/h (p < 0.001) and from 3.0 (IQR = 1.9) to 0.3 (IQR = 0.3) mg/dl (p < 0.001) after 12 months of treatment. A steroid-sparing effect was observed from the third month of treatment (p < 0.01). Thirteen patients (65%) were still on treatment at the last follow-up visit (median duration of treatment 17 (IQR = 38) months). The presence of R92Q mutation in a symptomatic relative (p = 0.022), the relapsing remitting disease course (p < 0.001) and the presence of migratory erythematous skin rashes during fever attacks (p = 0.005) were associated with complete efficacy of IL-1 inhibitors. Conclusions: R92Q patients showed a favourable response to ANA and CAN, particularly when the mutation segregated in a family member and when a relapsing-remitting disease course or TNF-α receptor-associated periodic syndrome (TRAPS) typical skin rash were observed. In the subgroup of patients not taking advantage of IL-1 blockage different molecular mechanisms underlying the autoinflammatory picture are likely to exist. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence.
- Author
-
Zanelli, Magda, Sanguedolce, Francesca, Zizzo, Maurizio, Palicelli, Andrea, Bassi, Maria Chiara, Santandrea, Giacomo, Martino, Giovanni, Soriano, Alessandra, Caprera, Cecilia, Corsi, Matteo, Ricci, Stefano, Ricci, Linda, and Ascani, Stefano
- Subjects
EXUDATES & transudates ,OTITIS media with effusion ,BONE marrow transplantation ,LYMPHOMAS ,OLDER patients ,KAPOSI'S sarcoma - Abstract
Background: Primary effusion lymphoma is a rare, aggressive large B-cell lymphoma strictly linked to infection by Human Herpes virus 8/Kaposi sarcoma-associated herpes virus. In its classic form, it is characterized by body cavities neoplastic effusions without detectable tumor masses. It often occurs in immunocompromised patients, such as HIV-positive individuals. Primary effusion lymphoma may affect HIV-negative elderly patients from Human Herpes virus 8 endemic regions. So far, rare cases have been reported in transplanted patients. The purpose of our systematic review is to improve our understanding of this type of aggressive lymphoma in the setting of transplantation, focusing on epidemiology, clinical presentation, pathological features, differential diagnosis, treatment and outcome. The role of assessing the viral serological status in donors and recipients is also discussed.Methods: We performed a systematic review adhering to the PRISMA guidelines. The literature search was conducted on PubMed/MEDLINE, Web of Science, Scopus, EMBASE and Cochrane Library, using the search terms "primary effusion lymphoma" and "post-transplant".Results: Our search identified 13 cases of post-transplant primary effusion lymphoma, predominantly in solid organ transplant recipients (6 kidney, 3 heart, 2 liver and 1 intestine), with only one case after allogenic bone marrow transplantation. Long-term immunosuppression is important in post-transplant primary effusion lymphoma commonly developing several years after transplantation. Kaposi Sarcoma occurred in association with lymphoma in 4 cases of solid organ recipients. The lymphoma showed the classical presentation with body cavity effusions in absence of tumor masses in 10 cases; 2 cases presented as solid masses, lacking effusions and one case as effusions associated with multiple organ involvement. Primary effusion lymphoma occurring in the setting of transplantation was more often Epstein Barr-virus negative. The prognosis was poor. In addition to chemotherapy, reduction of immunosuppressive treatment, was generally attempted.Conclusions: Primary effusion lymphoma is a rare, but often fatal post-transplant complication. Its rarity and the difficulty in achieving the diagnosis may lead to miss this complication. Clinicians should suspect primary effusion lymphoma in transplanted patients, presenting generally with unexplained body cavity effusions, although rare cases with solid masses are described. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.
- Author
-
Gaggiano, Carla, Rigante, Donato, Hernández-Rodríguez, José, Vitale, Antonio, Tarsia, Maria, Soriano, Alessandra, Lopalco, Giuseppe, Iannone, Florenzo, Abdel Jaber, Masen, Giacomelli, Roberto, Wiȩsik-Szewczyk, Ewa, Cattalini, Marco, Frassi, Micol, Piga, Matteo, Ragab, Gaafar, Sota, Jurgen, Zunica, Fiammetta, Floris, Alberto, Sabato, Vito, and Hegazy, Mohamed Tharwat
- Abstract
Background: This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition. Methods: Clinical data of patients treated with ANA or CAN for recurrent inflammatory attacks due to the presence of the R92Q variant were retrospectively collected and analysed. Results: Data about 20 treatment courses with IL-1 inhibitors (16 with ANA and 4 with CAN) from 19 patients were collected. Mean age at disease onset was 20.2 ± 14.8 years. In 5 cases (26%) the R92Q variant was found in a family member affected by recurrent fever. The therapeutic response was complete in 13(68%) and partial in 2 patients (11%); treatment failure was observed in 4 cases (21%). Median AIDAI decreased from 10 (interquartile range [IQR] = 28) to 0 (IQR = 1) at the 12-month follow-up visit (p < 0.001). Mean ESR and median CRP dropped respectively from 40.8 ± 24.8 to 9.1 ± 4.5 mm/h (p < 0.001) and from 3.0 (IQR = 1.9) to 0.3 (IQR = 0.3) mg/dl (p < 0.001) after 12 months of treatment. A steroid-sparing effect was observed from the third month of treatment (p < 0.01). Thirteen patients (65%) were still on treatment at the last follow-up visit (median duration of treatment 17 (IQR = 38) months). The presence of R92Q mutation in a symptomatic relative (p = 0.022), the relapsing remitting disease course (p < 0.001) and the presence of migratory erythematous skin rashes during fever attacks (p = 0.005) were associated with complete efficacy of IL-1 inhibitors. Conclusions: R92Q patients showed a favourable response to ANA and CAN, particularly when the mutation segregated in a family member and when a relapsing-remitting disease course or TNF-α receptor-associated periodic syndrome (TRAPS) typical skin rash were observed. In the subgroup of patients not taking advantage of IL-1 blockage different molecular mechanisms underlying the autoinflammatory picture are likely to exist. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: a tricky diagnosis of a gastric case.
- Author
-
Zanelli, Magda, Zizzo, Maurizio, Sanguedolce, Francesca, Martino, Giovanni, Soriano, Alessandra, Ricci, Stefano, Castro Ruiz, Carolina, Annessi, Valerio, and Ascani, Stefano
- Subjects
LYMPHOPROLIFERATIVE disorders ,GASTROINTESTINAL system ,SMALL intestine ,CELIAC disease ,COLON (Anatomy) ,CASTLEMAN'S disease ,LACTOSE intolerance - Abstract
Background: Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract is a rare low-grade clonal lymphoid proliferation, included as a provisional entity in the current World Health Organization classification. The disease is generally localized to the gastrointestinal tract, mainly small bowel and colon. Involvement of other organs is infrequently reported. The majority of patients show a protracted clinical course with persistent disease. A prolonged survival, even without treatment, is common.Case Presentation: A 28-year-old woman had a 2-year history of dyspepsia and lactose intolerance. Autoimmune diseases and celiac disease were excluded. No gross lesions were identified by endoscopy. Multiple gastric biopsies showed a small-sized lymphoid infiltrate, expanding the lamina propria, with a non-destructive appearance. The lymphoid cells were positive for CD3, CD4, CD5, CD7 and negative for CD20, CD8, CD56, CD103, PD1, CD30, ALK1, CD10, BCL6, perforin, TIA-1, Granzyme B and Epstein-Barr virus-encoded RNA. KI-67 index was low (5%). Molecular analysis revealed a clonal T-cell receptor γ rearrangement. Bone marrow was microscopically free of disease, but molecular testing identified the same T-cell receptor γ rearrangement present in the gastric biopsies. After the diagnosis of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, the patient received steroid therapy, only for 2 months. She is alive, with a stable disease restricted to the stomach, at 12 months from diagnosis.Conclusions: Indolent T-cell lymphoproliferative disorder is usually a disease of adulthood (median age: 51 yrs). The small bowel and colon are the sites most commonly involved. Our case occurred in a young woman and affected the stomach, sparing small intestine and colon. Clonality testing identified involvement of bone marrow, a site infrequently affected in this disease. Our aim is focusing on the main diagnostic issues. If appropriate immunostainings and molecular analysis are not performed, the subtle infiltrate may be easily overlooked. The risk of misdiagnosis as more aggressive lymphomas, causing patient overtreatment, needs also to be considered. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.
- Author
-
Gaggiano, Carla, Vitale, Antonio, Obici, Laura, Merlini, Giampaolo, Soriano, Alessandra, Viapiana, Ombretta, Cattalini, Marco, Maggio, Maria Cristina, Lopalco, Giuseppe, Montin, Davide, Jaber, Masen Abdel, Dagna, Lorenzo, Manna, Raffaele, Insalaco, Antonella, Piga, Matteo, La Torre, Francesco, Berlengiero, Virginia, Gelardi, Viviana, Ciarcia, Luisa, and Emmi, Giacomo
- Subjects
TUMOR necrosis factors ,AGE of onset ,ABDOMINAL pain ,SYNDROMES ,AGE groups ,ANTI-NMDA receptor encephalitis - Abstract
This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients' data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p < 0.05). With reference to clinical features during attacks, pericarditis and myalgia were reported more frequently in the context of adult-onset disease than in the pediatric age (with p < 0.01 and p < 0.05 , respectively), while abdominal pain was present in 84% of children and in 25% of adults (p < 0.01). Abdominal pain was significantly associated also to the presence of HP mutations (p < 0.01), while oral aphthosis was more frequently found in the LP variant group (p < 0.05). Systemic amyloidosis occurred in 25% of subjects carrying HP variants. As concerns laboratory features, HP mutations were significantly associated to higher ESR values (p < 0.01) and to the persistence of steadily elevated inflammatory markers during asymptomatic periods (p < 0.05). The presence of mutations involving a cysteine residue, abdominal pain, and lymphadenopathy during flares significantly correlated with the risk of developing amyloidosis and renal impairment. Conversely, the administration of colchicine negatively correlated to the development of pathologic proteinuria (p < 0.05). Both NSAIDs and colchicine were used as monotherapy more frequently in the LP group compared to the HP group (p < 0.01). Biologic agents were prescribed to 49 (61%) patients; R92Q subjects were more frequently on NSAIDs monotherapy than other patients (p < 0.01); nevertheless, they required biologic therapy in 53.1% of cases. At disease onset, the latest classification criteria for TRAPS were fulfilled by 64/80 (80%) patients (clinical plus genetic items) and 46/80 (57.5%) patients (clinical items only). No statistically significant differences were found in the sensitivity of the classification criteria according to age at onset and according to genotype (p < 0.05). This study describes one of the widest cohorts of TRAPS patients in the literature, suggesting that the clinical expression of this syndrome is more influenced by the penetrance of the mutation rather than by the age at onset itself. Given the high phenotypic heterogeneity of the disease, a definite diagnosis should rely on both accurate working clinical assessment and complementary genotype. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Editorial: Autoinflammatory Diseases: From Genes to Bedside.
- Author
-
Aksentijevich, Ivona, Soriano, Alessandra, and Hernández-Rodríguez, José
- Subjects
PHARYNGITIS ,PURE red cell aplasia - Abstract
Keywords: autoinflammatory diseases; genotype/phenotype correlations; inflammasome; ubiquitinopathies; hyperinflammatory state; epigenetics; dermatopathology; treatment EN autoinflammatory diseases genotype/phenotype correlations inflammasome ubiquitinopathies hyperinflammatory state epigenetics dermatopathology treatment 1 4 4 06/24/20 20200619 NES 200619 The year 2019 marked the 20th anniversary of the formal recognition of autoinflammatory diseases as a distinct group of rheumatological conditions, following the identification of the gene mutated in patients with a dominantly inherited periodic fever known as familial Hibernian fever (FHF) ([1]). Prior to this time, the only recognized periodic fever disease was familial Mediterranean fever (FMF) and patients presenting with similar symptoms, irrespective of inheritance pattern, were suspected to have a variant FMF. The disease was renamed tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS) and the term autoinflammation was coined to describe new diseases of the innate immune system ([1]). Targeted cytokine therapies, in particular anti-IL1 and anti-TNF, have been efficacious and with minimal side effects in treating patients with autoinflammation even without a known molecular cause of disease. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
14. Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
- Author
-
Soriano, Alessandra, Soriano, Marco, Espinosa, Gerard, Manna, Raffaele, Emmi, Giacomo, Cantarini, Luca, and Hernández-Rodríguez, José
- Subjects
PHARYNGITIS ,CRYOPYRIN-associated periodic syndromes ,FAMILIAL Mediterranean fever ,TUMOR necrosis factors ,MEVALONATE kinase ,THERAPEUTICS - Abstract
Monogenic autoinflammatory diseases are rare conditions caused by genetic abnormalities affecting the innate immunity. Previous therapeutic strategies had been mainly based on results from retrospective studies and physicians' experience. However, during the last years, the significant improvement in their genetic and pathogenic knowledge has been accompanied by a remarkable progress in their management. The relatively recent identification of the inflammasome as the crucial pathogenic mechanism causing an aberrant production of interleukin 1β (IL-1β) in the most frequent monogenic autoinflammatory diseases led to the introduction of anti–IL-1 agents and other biologic drugs as part of the previously limited therapeutic armamentarium available. Advances in the treatment of autoinflammatory diseases have been favored by the use of new biologic agents and the performance of a notable number of randomized clinical trials exploring the efficacy and safety of these agents. Clinical trials have contributed to increase the level of evidence and provided more robust therapeutic recommendations. This review analyzes the treatment of the most frequent monogenic autoinflammatory diseases, namely, familial Mediterranean fever, tumor necrosis factor receptor–associated periodic fever syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, and cryopyrin-associated periodic syndromes, together with periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome, which is the most common polygenic autoinflammatory disease in children, also occurring in adult patients. Finally, based on the available expert consensus recommendations and the highest level of evidence of the published studies, a practical evidence-based guideline for the treatment of these autoinflammatory diseases is proposed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network.
- Author
-
Vitale, Antonio, Sota, Jurgen, Obici, Laura, Ricco, Nicola, Maggio, Maria Cristina, Cattalini, Marco, Ruscitti, Piero, Caso, Francesco, Manna, Raffaele, Viapiana, Ombretta, Caggiano, Valeria, Emmi, Giacomo, Insalaco, Antonella, Montin, Davide, Licciardi, Francesco, Soriano, Alessandra, Dagna, Lorenzo, Salvarani, Carlo, Lamacchia, Vittoria, and Hernández-Rodríguez, José
- Subjects
TUMOR necrosis factor receptors ,TUMOR treatment ,COLCHICINE - Abstract
Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in a complete response in 3 (12.5%) cases, partial response in 14 (58.3%) patients, and lack of response in 7 (29.2%) patients. There were not significant differences in colchicine response between pediatric and adult disease onset (p = 0.42), between low- and high-penetrance mutations (p = 0.62), and according to different dosages (p = 0.66). No significant differences were identified in the frequency of specific disease manifestations between patients experiencing any response to colchicine and patients with lack of response. Conclusions. Colchicine monotherapy is useful in a low percentage of TRAPS patients; nevertheless, it could be attempted in patients with milder phenotypes and at a lower risk of developing reactive amyloidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases.
- Author
-
Bonacini, Martina, Soriano, Alessandra, Cimino, Luca, De Simone, Luca, Bolletta, Elena, Gozzi, Fabrizio, Muratore, Francesco, Nicastro, Maria, Belloni, Lucia, Zerbini, Alessandro, Fontana, Luigi, Salvarani, Carlo, and Croci, Stefania
- Subjects
AQUEOUS humor ,IRIDOCYCLITIS ,BEHCET'S disease ,UVEITIS ,INDIVIDUALIZED medicine - Abstract
Non-infectious uveitis are intraocular inflammatory conditions caused by dysregulated activation of the immune response without any detectable infectious agents. The aim of this study was to explore potential markers and therapeutic targets for two distinct types of non-infectious uveitis associated with Behçet's disease (BD) and Vogt Koyanagi Harada (VKH) disease. Concentrations of 27 cytokines were investigated in aqueous humor (AH) samples from patients with active uveitis vs. healthy controls (HC) (n = 10 patients with BD-associated uveitis; n = 10 patients with VKH-associated uveitis; n = 10 HC) using the Bio-Plex Pro
TM human cytokine group I panel. Additionally, leukocytes in AH samples were counted with hemocytometers and characterized by flow cytometry. Eleven cytokines were differentially expressed between patients with uveitis and HC with a median concentration greater than 10 pg/ml. IL-6, IP-10, G-CSF, and IFNγ showed higher concentrations in AH samples from both BD and VKH patients while IL-2, IL-8, IL-13, TNFα, eotaxin, IL-1ra showed statistically significant higher concentrations only in AH samples from BD patients. GM-CSF was the sole cytokine with an opposite profile showing decreased levels in AH samples from BD patients. IL-1ra and IL-6 were detected at higher frequencies in AH samples from BD and VKH patients compared with those from HC while IFNγ and TNFα were not detected in HC. The concentrations of IL-6, IL-8, IP-10, G-CSF, IFNγ, TNFα, eotaxin, IL-1ra positively correlated with the concentrations of leukocytes in AH, suggesting that such cytokines can be produced by immune cells and/or attract and/or promote proliferation and survival of immune cells in these types of uveitis. The correlation matrix of cytokine concentrations in AH samples revealed that IFNγ, TNFα, eotaxin, IL-6, G-CSF highly correlated each other. The ratios of cytokine concentrations between AH and plasma intra-individuals showed that IL-2, IL-6, IP-10, GM-CSF were increased intraocularly. In conclusion, AH sampling followed by multiplex analysis of cytokines should be fostered in non-infectious uveitis to identify cytokines dysregulated intraocularly in each individual laying the groundwork for precision medicine. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.
- Author
-
Bettiol, Alessandra, Silvestri, Elena, Di Scala, Gerardo, Amedei, Amedeo, Becatti, Matteo, Fiorillo, Claudia, Lopalco, Giuseppe, Salvarani, Carlo, Cantarini, Luca, Soriano, Alessandra, and Emmi, Giacomo
- Subjects
THERAPEUTICS ,INTERLEUKIN-1 ,META-analysis ,DRUG side effects ,SYNDROMES - Abstract
Behçet's syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) represent a promising therapeutic alternative in BS. To date, evidence on the use of ANA, CAN, and GEV is mainly based on small isolated studies or case series, and the real place of anti-IL1 agents in the treatment of BS is still unclear. We performed a systematic review of current evidence on the efficacy and safety of anti-IL1 agents in BS. The PubMed search yielded a total of 398 references, from which we retrieved 24 studies for inclusion (4 clinical trials, 6 observational studies, 14 case reports, case series or letters to the editor). Four studies evaluated the overall efficacy of IL-1 inhibitors, 15 studies focused on the specific efficacy of ANA, whereas efficacy of CAN and GEV was evaluated in 8 and 3 studies, respectively. Both ANA and CAN were associated with good control of mucocutaneous and ocular manifestations. ANA resulted effective also for osteoarticular manifestations. GEV was studied only for ocular manifestations, but gave contrasting results. Discordant evidence supports the use of ANA and CAN in pediatric setting and for first-line treatment of general BS manifestations. Most frequent side effects were local or diffuse cutaneous reactions and injection site reactions, particularly for ANA treatment. Blocking the IL-1 pathway could be an effective therapeutic strategy in particular BS involvements. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease.
- Author
-
Bonacini, Martina, Soriano, Alessandra, Zerbini, Alessandro, Calò, Eleonora, Cimino, Luca, Muratore, Francesco, Fontana, Luigi, Braglia, Luca, Parmeggiani, Maria, Salvarani, Carlo, and Croci, Stefania
- Subjects
BEHCET'S disease ,KILLER cells ,T cells ,T cell differentiation ,DIAGNOSIS ,THERAPEUTICS ,PHYSIOLOGY - Abstract
Behçet disease (BD) is an inflammatory systemic disease with a fluctuating course, which can affect the skin, eyes, central nervous system, musculoskeletal, gastrointestinal, and vascular systems. No laboratory tests are currently available for the diagnosis of BD and monitoring disease activity. Moreover there is a lack of knowledge on BD pathogenesis. This study focused on circulating Natural Killer (NK), NKT and T cells evaluated as CD3
neg CD56pos , CD3pos CD56pos , and CD3pos CD56neg . Peripheral blood mononuclear cells (PBMCs) were collected from 38 BD patients and 20 healthy controls (HC). The frequencies of NK, NKT, and T cells expressing CD16, CD69, NKG2D, Nkp30, Nkp46, and NKG2A were assessed by flow cytometry. Cytotoxic potential of NK cells was evaluated by flow cytometry as the percentage of cells expressing the degranulation marker CD107a after incubation with K562 cells. The levels of 27 cytokines were determined in plasma with a multiplex bead-based assay. Higher percentages of NK, NKT, and T cells expressing NKG2D were detected in PBMCs of BD patients than HC. ROC curve analysis showed that the evaluation of NKG2Dpos NK, NKT, and T cell percentages discriminated between BD patients and HC. Moreover, there was a positive correlation between the BD Current Activity Form (BDCAF) scores and the frequencies of NKG2Dpos NK and NKT cells. A higher frequency of NK cells expressing CD107a was induced in PBMCs from BD patients than HC after incubation with K562 cells. Concentrations of IL-5, IL-6, IL-10, IL-13, IP-10, and MIP-1β were higher in plasma of BD patients than HC. Monitoring the frequencies of NKG2Dpos lymphocytes could help the clinicians in BD patients management. In addition, the increased expression of NKG2D in BD patients is likely involved in disease pathogenesis. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
- Author
-
Sota, Jurgen, Vitale, Antonio, Insalaco, Antonella, Sfriso, Paolo, Lopalco, Giuseppe, Emmi, Giacomo, Cattalini, Marco, Manna, Raffaele, Cimaz, Rolando, Priori, Roberta, Talarico, Rosaria, de Marchi, Ginevra, Frassi, Micol, Gallizzi, Romina, Soriano, Alessandra, Alessio, Maria, Cammelli, Daniele, Maggio, Maria Cristina, Gentileschi, Stefano, and Marcolongo, Renzo
- Subjects
CHEMICAL inhibitors ,INTERLEUKIN-1 ,MEDICATION safety ,DRUG side effects ,ADVERSE health care events - Abstract
A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 patients/year. Safety concerns were more frequent among patients aged ≥ 65 years compared with patients < 16 years (p = 0.002). No differences were detected in the frequency of safety concerns between monotherapy and combination therapy with immunosuppressants (p = 0.055), but a significant difference was observed when injection site reactions were excluded from AE (p = 0.01). No differences were identified in relation to gender (p = 0.462), different lines of biologic therapy (p = 0.775), and different dosages (p = 0.70 ANA; p = 0.39 CAN). The overall drug retention rate was significantly different according to the occurrence of safety concerns (p value < 0.0001); distinguishing between ANA and CAN, significance was maintained only for ANA (p < 0.0001 ANA; p > 0.05 CAN). Treatment duration was the only variable associated with onset of AE (OR = 0.399 [C.I. 0.250-0.638], p = 0.0001). ANA and CAN have shown an excellent safety profile; the risk for AE and sAE tends to decrease over time from the start of IL-1 inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression.
- Author
-
Soriano, Alessandra, Smerieri, Nazareno, Bonilauri, Stefano, De Marco, Loredana, Cavazza, Alberto, and Salvarani, Carlo
- Subjects
GRANULOMATOSIS with polyangiitis ,INTESTINAL perforation ,CYTOMEGALOVIRUS diseases ,IMMUNOSUPPRESSION ,COLON diseases ,SEVERITY of illness index - Abstract
Granulomatosis with polyangiitis (GPA) is a small-vessel necrotizing granulomatous vasculitis typically involving upper airways, lungs, and kidneys, which may lead to end-organ damage and life-threatening complications. Major infections during GPA course represent a considerable concern in the management of the disease. Cytomegalovirus (CMV) infection and disease are rare but significant complications in the course of GPA being associated with high morbidity and mortality rates. Colonic perforation due to CMV colitis is exceedingly rare and has so far almost exclusively been documented in HIV, renal transplant, and systemic lupus erythematosus patients. We reported the case of a patient affected with upper airways-limited GPA who developed acute renal failure from rapidly progressive glomerulonephritis and then experienced colonic perforation due to CMV colitis a few weeks after immunosuppressive treatment with high-dose steroids and cyclophosphamide (CYC) for remission induction of the disease. We also reviewed the literature on CMV-related gastro-intestinal complications in the course of GPA and discussed contributing factors to severe manifestations of CMV infection and its reactivation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
- Author
-
Muratore, Francesco, Pazzola, Giulia, Soriano, Alessandra, Pipitone, Nicolò, Croci, Stefania, Bonacini, Martina, Boiardi, Luigi, and Salvarani, Carlo
- Abstract
Despite the progress in the last years on the field of vasculitides, there are several unmet needs regarding classification, disease activity assessment, predictors of flares and complications, and type of treatment for the different forms. The 1990 American College of Rheumatology (ACR) classification criteria currently used to define giant cell arteritis and Takayasu arteritis were designed to discriminate between different types of vasculitides but not to differentiate vasculitis from other disorders. Recently, efforts have been made to overcome the shortcomings of the ACR criteria. The lack of an accepted definition of disease activity in large-vessel vasculitides presents a major challenge in creating useful and valid outcome tools for the assessment of disease course. Identification of predictors of flares can aid in optimizing therapeutic strategies, minimizing disease flares, and reducing treatment-related side effects. It is furthermore important to recognize and characterize the risk factor that might predict the manifestations associated with poor outcome and prognosis. Two RCTs have evidenced the efficacy of tocilizumab in addition to glucocorticoids (GCs) in the treatment of giant cell arteritis (GCA). However, the role of tocilizumab or other biological agents without GCs needs to be investigated. Recent observational studies have suggested that rituximab is also effective in patients with eosinophilic granulomatosis with polyangiitis and in antineutrophil cytoplasmic antibodies (ANCA)-negative patients with granulomatosis with polyangiitis and microscopic polyangiitis. Rituximab or anti-TNF alfa may represent a possible alternative therapy in case of refractory or difficult to treat polyarteritis nodosa (PAN) patients. The new International Criteria for Behçet’s Disease have shown a better sensitivity and a better accuracy compared to the older International Study Group on Behçet’s Disease criteria. The EULAR recommendations for the management of Behçet’s disease (BD) have been recently updated. However, the treatment of refractory disease is still a real challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.
- Author
-
Ruiz-Ortiz, Estíbaliz, Iglesias, Estíbaliz, Soriano, Alessandra, Buján-Rivas, Segundo, Español-Rego, Marta, Castellanos-Moreira, Raul, Tomé, Adrià, Yagüe, Jordi, Antón, Jordi, and Hernández-Rodríguez, José
- Subjects
TUMOR necrosis factors ,GENETIC mutation ,MYALGIA - Abstract
Background: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease caused by mutations in the TNFRSF1A gene. R92Q, a low-penetrance variant, is usually associated with a milder TRAPS phenotype than structural or pathogenic mutations. No studies differentiating R92Q-related disease in patients with pediatric and adult onset have been performed to date. Objective: To analyze clinical features and disease outcomes in patients diagnosed with TRAPS associated with R92Q variant and to investigate differences between patients with pediatric and adult disease onset. Methods: A retrospective review of patients with R92Q-related disease from four reference centers for autoinflammatory diseases was performed. Clinical and laboratory features, family history of autoinflammatory diseases, treatments received, and outcomes during follow-up were recorded and separately analyzed in pediatric and adult patients. Our results were included in the analysis with other reported pediatric and adult R92Qrelated disease series. results: Our series encompassed 18 patients (9 females and 9 males) with R92Q variant. In 61% of patients, disease onset occurred during infancy and in 39%, during adulthood, with a median diagnostic delay of 5 years and a follow-up of 5.4 years. A positive family history of autoinflammatory disease was detected in 28% of patients. All patients presented with febrile recurrent episodes. Other common symptoms included arthralgia/arthritis (61%), myalgia (39%), asthenia/fatigue (44%), abdominal pain (39%), headache (33%), odynophagia (33%), skin rash (28%), and chest pain (22%). During attacks, 80% of patients increased acute phase reactants levels. No patient had developed amyloidosis during the study period. At the end of follow-up, 28% of patients were asymptomatic and treatment free, 50% were receiving non-steroidal anti-inflammatory drugs or glucocorticoids on demand, and 22% were being treated with biologic agents. When differences between pediatric and adult patients were globally analyzed, adults tended to have longer attacks duration and presented more frequently with chest pain and headache, while abdominal pain, vomiting, cervical adenitis, and pharyngitis predominated in pediatric patients. No differences in outcomes and treatment requirements were observed in both age groups. conclusion: This study has contributed to characterize R92Q-related disease by identifying trends in disease phenotypes depending on the age at disease onset. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. A novel bedside test for ACPA: the CCPoint test is moving the laboratory to the rheumatologist's office.
- Author
-
Goddard, Gisele, Soriano, Alessandra, Gilburd, Boris, Lidar, Merav, Kivity, Shaye, Kopilov, Ron, Langevitz, Pnina, Shoenfeld, Yehuda, and Agmon-Levin, Nancy
- Abstract
Rheumatoid Arthritis (RA) is an autoimmune destructive joint disease affecting 1 % of the general population. In recent years, the benefits of identifying RA at an early stage and initiating therapy before joint damage occurs have been acknowledged. An elevated anti-citrullinated peptide antibody (ACPA) level serves as a marker for the early diagnosis of RA. Often the diagnosis is delayed because conventional methods of antibody detection require referral to a specific laboratory. In the current study, we determined the diagnostic accuracy of a new lateral flow point-of-care kit available for ACPA detection in the rheumatologist office. The presence of ACPA was determined by the visually read, qualitative rapid CCPoint test (Euro-Diagnostica, Malmö, Sweden) compared to routinely used ELISA assays (Immunoscan CCPlus-Euro-Diagnostica, Sweden, and QuantLite CCP3-INOVA Diagnostics Inc., USA), in the sera of 184 patients: early RA( n = 38), established RA ( n = 84), inflammatory arthritis( n = 34) and systemic lupus erythematosus (SLE) ( n = 28). ACPA was detected in 18/38(47 %), 53/84(63 %), 2/34(6 %) and 2/28(7 %) of patients with early RA, established RA, inflammatory arthritis and SLE, respectively. The sensitivity and specificity, negative and positive predictive values of the CCPoint test were equivalent to the Immunoscan CCPlus and Quanta Lite CCP3 ELISA assays. Correlation between ACPA positive results detected in the different assays was 97 %, while negative agreement reached 98 %. Excellent correlation (100 %) was observed between CCPoint results obtained using capillary blood versus serum. CCPoint is a novel technology that allows for a rapid accurate analysis of ACPA and diagnosis during the patient's visit in the rheumatologist office. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
- Author
-
Fabiani, Claudia, Vitale, Antonio, Emmi, Giacomo, Vannozzi, Lorenzo, Lopalco, Giuseppe, Guerriero, Silvana, Orlando, Ida, Franceschini, Rossella, Bacherini, Daniela, Cimino, Luca, Soriano, Alessandra, Frediani, Bruno, Galeazzi, Mauro, Iannone, Florenzo, Tosi, Gian, Salvarani, Carlo, and Cantarini, Luca
- Subjects
BEHCET'S disease ,ADALIMUMAB ,DRUG efficacy ,MEDICATION safety ,UVEITIS treatment ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
The study aim was to evaluate the efficacy of adalimumab (ADA) in a large series of Behçet's disease (BD)-related uveitis. We performed a multicenter retrospective observational study including 40 selected patients (66 eyes) receiving ADA. Clinical data were retrospectively analyzed at baseline, at 3 and 12 months of treatment. Primary end point was reduction of ocular inflammatory flares. Secondary end points were improvement of best corrected visual acuity (BCVA), reduction of macular thickness measured by optical coherence tomography (OCT), reduction in the occurrence of vasculitis assessed by fluorescein angiography (FA), and evaluation of statistically significant differences between patients treated with ADA monotherapy and those undergoing ADA plus DMARDs and in patients firstly treated with ADA compared to patients previously administered with other biologics; ADA steroid sparing effect was also evaluated. During the first 12 months of ADA therapy, the number of flares significantly decreased from 200 flares/100 patients/year to 8.5 flares/100 patients/year ( p < 0.0001). Similarly, BCVA improved if compared to baseline (7.4 ± 2.9 versus 8.5 ± 2.1, p = 0.03). OCT findings significantly improved showing a mean reduction of central macular thickness (CMT) of 27.27 ± 42.8 μm at the end of follow-up ( p < 0.006). FA identified retinal vasculitis in 22 cases at baseline (55%), 8 (20%) cases after 3 months, and in only one (2.5%) case at 12-month follow-up. FA improvement was highly significant at 3- and 12-month follow-up if compared to baseline ( p < 0.0001 and p = 0.006, respectively). ADA is highly effective and safe for the treatment of BD-related uveitis, providing a long-term control of ocular inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Association between seasonal factors and multiple sclerosis.
- Author
-
Watad, Abdulla, Azrielant, Shir, Soriano, Alessandra, Bracco, Danielle, Abu Much, Arsalan, and Amital, Howard
- Subjects
MULTIPLE sclerosis ,SEASONAL variations of diseases ,CENTRAL nervous system physiology ,NEUROLOGICAL disorders ,DEMYELINATION ,RELAPSING fever - Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system. MS is causing progressive and relapsing neurological disability, due to demyelination and axonal damage. The etiopathogenesis of MS is poorly understood. A number of environmental factors have been previously suggested, including: month of birth, vitamin D levels, smoking and viral infections. Previous studies assessing seasonal variation of relapses in multiple sclerosis have had conflicting results. The aim of this review is to assess the association between seasonal factors and MS, in terms of disease onset, relapses and activity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Genetics and Origin of Antiphospholipid Syndrome.
- Author
-
Soriano, Alessandra, Blank, Miri, and Shoenfeld, Yehuda
- Published
- 2015
- Full Text
- View/download PDF
27. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.
- Author
-
Vitale, Antonio, Insalaco, Antonella, Sfriso, Paolo, Lopalco, Giuseppe, Emmi, Giacomo, Cattalini, Marco, Manna, Raffaele, Cimaz, Rolando, Priori, Roberta, Talarico, Rosaria, Gentileschi, Stefano, De Marchi, Ginevra, Frassi, Micol, Gallizzi, Romina, Soriano, Alessandra, Alessio, Maria, Cammelli, Daniele, Maggio, Maria C., Marcolongo, Renzo, and La Torre, Francesco
- Subjects
INTERLEUKIN-1 ,RHEUMATOLOGISTS - Abstract
Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA was administered in 421 (80.04%) courses, CAN in 105 (19.96%). Sixty-two (32.1%) patients had been treated with both agents. IL-1 inhibitors were employed in 38 different indications (37 with ANA, 16 with CAN). Off-label use was more frequent for ANA than CAN (p < 0.0001). ANA was employed as first-line biologic approach in 323 (76.7%) cases, while CAN in 37 cases (35.2%). IL-1 inhibitors were associated with corticosteroids in 285 (54.18%) courses and disease modifying anti-rheumatic drugs (DMARDs) in 156 (29.65%). ANA dosage ranged from 30 to 200mg/day (or 1.0-2.0 mg/kg/day) among adults and 2-4 mg/kg/day among children; regarding CAN, the most frequently used posologies were 150mg every 8 weeks, 150mg every 4 weeks and 150mg every 6 weeks. The frequency of failure was higher among patients treated with ANA at a dosage of 100 mg/day than those treated with 2 mg/kg/day (p = 0.03). Seventy-six patients (14.4%) reported an adverse event (AE) and 10 (1.9%) a severe AE. AEs occurred more frequently after the age of 65 compared to both children and patients aged between 16 and 65 (p = 0.003 and p = 0.03, respectively). Conclusions: IL-1 inhibitors are mostly used off-label, especially ANA, during adulthood. The high frequency of good clinical responses suggests that IL-1 inhibitors are used with awareness of pathogenetic mechanisms; adult healthcare physicians generally employ standard dosages, while pediatricians are more prone in using a weight-based posology. Dose adjustments and switching between different agents showed to be effective treatment strategies. Our data confirm the good safety profile of IL-1 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Vitamin D and Systemic Lupus Erythematosus: Myth or Reality?
- Author
-
Watad, Abdulla, Neumann, Shana G., Soriano, Alessandra, Amital, Howard, and Shoenfeld, Yehuda
- Published
- 2016
29. Sjögren's syndrome presenting with isolated sensory axonal polyneuropathy.
- Author
-
Di Lazzaro, Vincenzo, Rigon, Amelia, Soriano, Alessandra, Capone, Fioravante, Corbetto, Marzia, Florio, Lucia, Afeltra, Antonella, Onetti Muda, Andrea, and Luigetti, Marco
- Subjects
SJOGREN'S syndrome ,ANTINUCLEAR factors - Published
- 2017
- Full Text
- View/download PDF
30. Comment on "Is the Never-Ending Story Still Unsolved? Beyond the Long Debate About Lateral Pelvic Lymph Node Dissection in Rectal Cancer".
- Author
-
Maurizio Zizzo, Zanelli, Magda, Sanguedolce, Francesca, Soriano, Alessandra, and Ascani, Stefano
- Published
- 2021
- Full Text
- View/download PDF
31. Is atherosclerosis accelerated in systemic sclerosis? Novel insights.
- Author
-
Soriano, Alessandra, Afeltra, Antonella, and Shoenfeld, Yehuda
- Published
- 2014
- Full Text
- View/download PDF
32. Immunization with vaccines and Sjögren's syndrome.
- Author
-
Soriano, Alessandra, Afeltra, Antonella, and Shoenfeld, Yehuda
- Subjects
SJOGREN'S syndrome ,AUTOIMMUNE diseases ,IMMUNOTHERAPY ,VACCINATION ,ETIOLOGY of diseases - Abstract
Sjögren's syndrome (SjS) is a systemic autoimmune disease with complex pathogenesis and still unknown etiology. Infections are listed among the main environmental factors triggering the disease in genetically predisposed individuals. Among other environmental factors, the role of immunization with vaccines in the etiopathogenesis of SjS has not yet been elucidated. Although immunization with vaccines is safe for the majority of subjects, in rare cases it can trigger or exacerbate autoimmune and rheumatic inflammatory conditions. In this paper we investigate the possible links between immunization with vaccines and the pathogenesis of SjS. The current scientific evidence about safety and efficacy of vaccines in the course of SjS are also reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Human papillomavirus vaccine and systemic lupus erythematosus.
- Author
-
Gatto, Mariele, Agmon-Levin, Nancy, Soriano, Alessandra, Manna, Raffaele, Maoz-Segal, Ramit, Kivity, Shaye, Doria, Andrea, and Shoenfeld, Yehuda
- Subjects
IMMUNIZATION complications ,AUTOIMMUNE diseases ,SYSTEMIC lupus erythematosus ,RHEUMATISM ,HUMAN papillomavirus vaccines ,DISEASE risk factors - Abstract
To investigate the association between human papillomavirus (HPV) vaccination and autoimmune manifestations compatible with systemic lupus erythematosus (SLE) or SLE-like disease, the medical history of six women who presented with SLE or SLE-like disease following HPV immunization was collected. Data regarding type of vaccine, number of immunization, family and personal, clinical and serological features, as well as response to treatments were analyzed. In the reported cases, several common features were observed, such as personal or familial susceptibility to autoimmunity or adverse response to a prior dose of the vaccine, both of which may be associated with a higher risk of post-vaccination autoimmunity. Favorable response to immunosuppressant was observed in all patients. In the current study, a temporal association between immunization with HPV vaccine and the appearance of a spectrum of SLE-like conditions is reported. Additionally, among the patients described, several common features were observed that may enable better identification of subjects at risk. Further studies are required to assess the safety of immunization with the HPV vaccine in patients with autoimmune-rheumatic diseases or in subject at risk of autoimmunity as well as the potential beneficial effect of preventive immunosuppressants. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
34. IL-1β Biological Treatment of Familial Mediterranean Fever.
- Author
-
Soriano, Alessandra, Verecchia, Elena, Afeltra, Antonella, Landolfi, Raffaele, and Manna, Raffaele
- Abstract
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder characterised by brief, recurring, self-limited episodes of fever and serositis resulting in abdominal, chest, joint and muscular pain; it is the most common of the periodic hereditary fevers and mostly affects Mediterranean populations. Daily administration of colchicine, a tricyclic alkaloid with anti-microtubule and anti-inflammatory properties, prevents the recurrence of FMF attacks and the development of secondary (AA) amyloidosis, the major long-tem complication of FMF. Colchicine is generally safe and well-tolerated; nevertheless, 5-10 % of FMF patients do not respond to conventional treatment, while another 2-5 % of patients are colchicine-intolerant because of toxicity issues, leading physicians to search for alternative therapeutic strategies. Recent new insights into the mechanisms of auto-inflammation add further proof to the efficacy of IL-1 targeting drugs in colchicine non-responder/intolerant FMF patients. A systematic study of relevant literature through PubMed/Medline was performed in order to identify publications reporting IL-1β biological treatment of FMF. Treatment methods, comorbidities, clinical response and side effects in literature case reports were analysed, as well as recent advances in the pathogenesis of auto-inflammation mechanisms in FMF and the causes of colchicine resistance or toxicity in common clinical practice. The paradigmatic experience of an FMF patient with severe FMF mutations (M694V/M694V) suffering from colchicine toxicity and successfully treated with anakinra is also reported. The present data show that anti-IL-1β biological treatment is actually a therapeutic option for FMF patients unresponsive or intolerant to colchicine or in FMF patients with concomitant vasculitis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3).
- Author
-
Zanelli, Magda, Sanguedolce, Francesca, Palicelli, Andrea, Zizzo, Maurizio, Martino, Giovanni, Caprera, Cecilia, Fragliasso, Valentina, Soriano, Alessandra, Gozzi, Fabrizio, Cimino, Luca, Masia, Francesco, Moretti, Marina, Foroni, Moira, De Marco, Loredana, Pellegrini, David, De Raeve, Hendrik, Ricci, Stefano, Tamagnini, Ione, Tafuni, Alessandro, and Cavazza, Alberto
- Subjects
B cells ,KILLER cells ,GASTROINTESTINAL tumors ,EPSTEIN-Barr virus ,LYMPHOPROLIFERATIVE disorders ,LYMPHOMAS ,T cells - Abstract
Simple Summary: The Epstein–Barr virus (EBV) is a commonly occurring virus, infecting more than 90% of the world population, often early in life. However, only a minority of individuals develop EBV-driven diseases at some point in their lifetime. EBV is associated with several neoplasms including epithelial, mesenchymal and lymphoid tumors. EBV-driven lymphoid proliferations encompass a wide spectrum of diseases with different biological behaviors, developing frequently, although not always, in conditions of immunosuppression. The diagnosis is often complicated and requires a strict combination of clinical, pathological and molecular findings. The aim of this review, divided into three parts, is to provide an update on EBV-driven lymphoproliferative disorders arising in the gastrointestinal tract. In this review, we discuss the chronic active EBV infection of T-cell and NK-cell type, its systemic form; extranodal NK/T-cell lymphoma, nasal type and post-transplant lymphoproliferative disorders. EBV is the first known oncogenic virus involved in the development of several tumors. The majority of the global population are infected with the virus early in life and the virus persists throughout life, in a latent stage, and usually within B lymphocytes. Despite the worldwide diffusion of EBV infection, EBV-associated diseases develop in only in a small subset of individuals often when conditions of immunosuppression disrupt the balance between the infection and host immune system. EBV-driven lymphoid proliferations are either of B-cell or T/NK-cell origin, and range from disorders with an indolent behavior to aggressive lymphomas. In this review, which is divided in three parts, we provide an update of EBV-associated lymphoid disorders developing in the gastrointestinal tract, often representing a challenging diagnostic and therapeutic issue. Our aim is to provide a practical diagnostic approach to clinicians and pathologists who face this complex spectrum of disorders in their daily practice. In this part of the review, the chronic active EBV infection of T-cell and NK-cell type, its systemic form; extranodal NK/T-cell lymphoma, nasal type and post-transplant lymphoproliferative disorders are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
- Author
-
Palicelli, Andrea, Croci, Stefania, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Zanelli, Magda, Chaux, Alcides, Cañete-Portillo, Sofia, Bonasoni, Maria Paola, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, Giordano, Guido, Landriscina, Matteo, and Carrieri, Giuseppe
- Subjects
CELLULAR signal transduction ,PROGRAMMED death-ligand 1 ,TUMOR microenvironment ,CYTOTOXIC T cells ,PROSTATE cancer ,PROGRAMMED cell death 1 receptors ,SUPPRESSOR cells - Abstract
The tumor microenvironment (TME) includes immune (T, B, NK, dendritic), stromal, mesenchymal, endothelial, adipocytic cells, extracellular matrix, and cytokines/chemokines/soluble factors regulating various intracellular signaling pathways (ISP) in tumor cells. TME influences the survival/progression of prostate cancer (PC), enabling tumor cell immune-evasion also through the activation of the PD-1/PD-L1 axis. We have performed a systematic literature review according to the PRISMA guidelines, to investigate how the PD-1/PD-L1 pathway is influenced by TME and ISPs. Tumor immune-escape mechanisms include suppression/exhaustion of tumor infiltrating cytotoxic T lymphocytes, inhibition of tumor suppressive NK cells, increase in immune-suppressive immune cells (regulatory T, M2 macrophagic, myeloid-derived suppressor, dendritic, stromal, and adipocytic cells). IFN-γ (the most investigated factor), TGF-β, TNF-α, IL-6, IL-17, IL-15, IL-27, complement factor C5a, and other soluble molecules secreted by TME components (and sometimes increased in patients' serum), as well as and hypoxia, influenced the regulation of PD-L1. Experimental studies using human and mouse PC cell lines (derived from either androgen-sensitive or androgen-resistant tumors) revealed that the intracellular ERK/MEK, Akt-mTOR, NF-kB, WNT and JAK/STAT pathways were involved in PD-L1 upregulation in PC. Blocking the PD-1/PD-L1 signaling by using immunotherapy drugs can prevent tumor immune-escape, increasing the anti-tumor activity of immune cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
- Author
-
Palicelli, Andrea, Croci, Stefania, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Zanelli, Magda, Chaux, Alcides, Cañete-Portillo, Sofia, Bonasoni, Maria Paola, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, Giordano, Guido, Landriscina, Matteo, and Carrieri, Giuseppe
- Subjects
PROGRAMMED death-ligand 1 ,PROSTATE cancer ,DNA sequencing ,HISTONE deacetylase inhibitors ,ANDROGEN receptors ,CHROMATIN - Abstract
Epigenetic alterations (including DNA methylation or miRNAs) influence oncogene/oncosuppressor gene expression without changing the DNA sequence. Prostate cancer (PC) displays a complex genetic and epigenetic regulation of cell-growth pathways and tumor progression. We performed a systematic literature review (following PRISMA guidelines) focused on the epigenetic regulation of PD-L1 expression in PC. In PC cell lines, CpG island methylation of the CD274 promoter negatively regulated PD-L1 expression. Histone modifiers also influence the PD-L1 transcription rate: the deletion or silencing of the histone modifiers MLL3/MML1 can positively regulate PD-L1 expression. Epigenetic drugs (EDs) may be promising in reprogramming tumor cells, reversing epigenetic modifications, and cancer immune evasion. EDs promoting a chromatin-inactive transcriptional state (such as bromodomain or p300/CBP inhibitors) downregulated PD-L1, while EDs favoring a chromatin-active state (i.e., histone deacetylase inhibitors) increased PD-L1 expression. miRNAs can regulate PD-L1 at a post-transcriptional level. miR-195/miR-16 were negatively associated with PD-L1 expression and positively correlated to longer biochemical recurrence-free survival; they also enhanced the radiotherapy efficacy in PC cell lines. miR-197 and miR-200a-c positively correlated to PD-L1 mRNA levels and inversely correlated to the methylation of PD-L1 promoter in a large series. miR-570, miR-34a and miR-513 may also be involved in epigenetic regulation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
- Author
-
Palicelli, Andrea, Croci, Stefania, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Zanelli, Magda, Chaux, Alcides, Cañete-Portillo, Sofia, Bonasoni, Maria Paola, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, Giordano, Guido, Landriscina, Matteo, and Carrieri, Giuseppe
- Subjects
LABORATORY mice ,PROGRAMMED death-ligand 1 ,INVESTIGATIONAL therapies ,CELL lines ,CELL migration ,PROTEIN-tyrosine kinases - Abstract
In prostate cancer (PC), the PD-1/PD-L1 axis regulates various signaling pathways and it is influenced by extracellular factors. Pre-clinical experimental studies investigating the effects of various treatments (alone or combined) may discover how to overcome the immunotherapy-resistance in PC-patients. We performed a systematic literature review (PRISMA guidelines) to delineate the landscape of pre-clinical studies (including cell lines and mouse models) that tested treatments with effects on PD-L1 signaling in PC. NF-kB, MEK, JAK, or STAT inhibitors on human/mouse, primary/metastatic PC-cell lines variably down-modulated PD-L1-expression, reducing chemoresistance and tumor cell migration. If PC-cells were co-cultured with NK, CD8+ T-cells or CAR-T cells, the immune cell cytotoxicity increased when PD-L1 was downregulated (opposite effects for PD-L1 upregulation). In mouse models, radiotherapy, CDK4/6-inhibitors, and RB deletion induced PD-L1-upregulation, causing PC-immune-evasion. Epigenetic drugs may reduce PD-L1 expression. In some PC experimental models, blocking only the PD-1/PD-L1 pathway had limited efficacy in reducing the tumor growth. Anti-tumor effects could be increased by combining the PD-1/PD-L1 blockade with other approaches (inhibitors of tyrosine kinase, PI3K/mTOR or JAK/STAT3 pathways, p300/CBP; anti-RANKL and/or anti-CTLA-4 antibodies; cytokines; nitroxoline; DNA/cell vaccines; radiotherapy/Radium-223). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.
- Author
-
Palicelli, Andrea, Bonacini, Martina, Croci, Stefania, Magi-Galluzzi, Cristina, Cañete-Portillo, Sofia, Chaux, Alcides, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Bonasoni, Maria Paola, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, Giordano, Guido, and Landriscina, Matteo
- Subjects
PROGRAMMED death-ligand 1 ,PROSTATE cancer ,BENIGN tumors ,CLONE cells ,DEEP brain stimulation - Abstract
Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically "hot" tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations.
- Author
-
Palicelli, Andrea, Bonacini, Martina, Croci, Stefania, Magi-Galluzzi, Cristina, Cañete-Portillo, Sofia, Chaux, Alcides, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Zanelli, Magda, Bonasoni, Maria Paola, De Marco, Loredana, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, and Giordano, Guido
- Subjects
PROGRAMMED death-ligand 1 ,IMMUNOHISTOCHEMISTRY ,OVERALL survival ,PROSTATE cancer ,PROGRAMMED cell death 1 receptors - Abstract
Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Subcutaneous marginal zone lymphoma: an unusual lipoma-like presentation.
- Author
-
Zanelli, Magda, Zizzo, Maurizio, Sanguedolce, Francesca, Soriano, Alessandra, Martino, Giovanni, Annessi, Valerio, and Ascani, Stefano
- Subjects
MUCOSA-associated lymphoid tissue lymphoma ,LYMPHOMAS ,LYMPHOID tissue ,B cell lymphoma ,BIOPSY ,COMBINED modality therapy ,COMPUTED tomography ,DIFFERENTIAL diagnosis ,TUMOR classification ,TREATMENT effectiveness ,LIPOMA ,TUMOR grading - Abstract
Dear Editor, A 50-year-old, hepatitis C virus (HCV)-negative, man developed multiple, palpable, soft subcutaneous nodules underlying a normal appearing skin and clinically resembling lipomas. (Right) Microscopic histological examination: dense and diffuse lymphoid infiltrate restricted to the subcutaneous tissue, sparing dermis, and epidermis MZL is a low-grade non-Hodgkin B cell lymphoma frequently affecting extranodal sites, spleen, and lymph nodes [[1]]. 20174: Lyon; IARC: World Health Organization: 978-9283244943 2 Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, Merli M, Rattotti S, Rossi D, Riboni R, Berti E, Magrini U, Bruno R, Gaidano G, Lazzarino M. Subcutaneous "lipoma-like" B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
42. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1).
- Author
-
Zanelli, Magda, Sanguedolce, Francesca, Palicelli, Andrea, Zizzo, Maurizio, Martino, Giovanni, Caprera, Cecilia, Fragliasso, Valentina, Soriano, Alessandra, Valle, Luca, Ricci, Stefano, Cavazza, Alberto, Merli, Francesco, Pileri, Stefano A., and Ascani, Stefano
- Subjects
HODGKIN'S disease ,ULCERS ,ORAL diseases ,GASTROINTESTINAL tumors ,IMMUNOPHENOTYPING ,LYMPHOMAS ,LYMPHOPROLIFERATIVE disorders ,EPSTEIN-Barr virus diseases ,DISEASE risk factors ,DISEASE complications - Abstract
Simple Summary: Epstein–Barr virus (EBV) infection usually occurs early in life. The virus persists throughout the lifespan in a latent phase mainly in B lymphocytes of immunocompetent hosts. Conditions of immunosuppression of variable origins may favor the emergence of EBV-linked lymphoid proliferations. This group of disorders, having EBV as common denominator, encompasses entities ranging from indolent diseases to aggressive lymphomas. In this review, consisting of three parts, we focus on EBV-linked lymphoid proliferations which may occur in the gastrointestinal tract. Our aim is to summarize the salient clinical, pathological, molecular and therapeutic data of this group of heterogeneous entities, often showing overlapping morphologic and immunophenotypic features despite the different clinical behavior. The correct diagnosis is essential in order to adopt the adequate treatment. In this part of the review, the available data on EBV biology, EBV-positive mucocutaneous ulcer, EBV-positive diffuse large B-cell lymphoma, not otherwise specified and classic Hodgkin lymphoma are discussed. EBV is the most common persistent virus in humans. The interaction of EBV with B lymphocytes, which are considered the virus reservoir, is at the base of the life-long latent infection. Under circumstances of immunosuppression, the balance between virus and host immune system is altered and hence, EBV-associated lymphoid proliferations may originate. These disorders encompass several entities, ranging from self-limited diseases with indolent behavior to aggressive lymphomas. The virus may infect not only B-cells, but even T- and NK-cells. The occurrence of different types of lymphoid disorders depends on both the type of infected cells and the state of host immunity. EBV-driven lymphoproliferative lesions can rarely occur in the gastrointestinal tract and may be missed even by expert pathologists due to both the uncommon site of presentation and the frequent overlapping morphology and immunophenotypic features shared by different entities. The aim of this review is to provide a comprehensive overview of the current knowledge of EBV-associated lymphoproliferative disorders, arising within the gastrointestinal tract. The review is divided in three parts. In this part, the available data on EBV biology, EBV-positive mucocutaneous ulcer, EBV-positive diffuse large B-cell lymphoma, not otherwise specified and classic Hodgkin lymphoma are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2).
- Author
-
Zanelli, Magda, Sanguedolce, Francesca, Palicelli, Andrea, Zizzo, Maurizio, Martino, Giovanni, Caprera, Cecilia, Fragliasso, Valentina, Soriano, Alessandra, Valle, Luca, Ricci, Stefano, Gozzi, Fabrizio, Cimino, Luca, Cavazza, Alberto, Merli, Francesco, Pileri, Stefano A., and Ascani, Stefano
- Subjects
LYMPHOMA diagnosis ,B cell lymphoma ,DIFFERENTIAL diagnosis ,GASTROINTESTINAL tumors ,LYMPHOPROLIFERATIVE disorders ,LYMPHOMAS ,EPSTEIN-Barr virus diseases - Abstract
Simple Summary: Epstein–Barr virus (EBV)-associated lymphoproliferative disorders have been garnering attention in recent years. EBV infects people primarily in their first years of life. The viral genome is maintained in a latent phase within the host cells, usually B-lymphocytes. The immunosuppression of different origins alters homeostasis between the virus and the host, enabling EBV-linked lymphoproliferative disorders to appear. Entities with different biological behaviors often share some morphological and phenotypic features, making the diagnosis complicated. Nodal and extra-nodal sites, including the gastrointestinal tract may be involved. This review, divided into three parts, aims to summarize the available clinical, pathological, molecular and therapeutic data on EBV-associated lymphoproliferative disorders involving the gastrointestinal tract. In this part of the review, we discuss plasmablastic lymphoma, extra-cavitary primary effusion lymphoma and Burkitt lymphoma. Epstein–Barr virus (EBV) is a common pathogen infecting people primarily early in life. The virus has the ability to persist throughout a person's life, usually in B lymphocytes. Conditions of immunodeficiency as well as the introduction of immunosuppressive therapies and the advent of transplant technologies has brought immunodeficiency-associated lymphoproliferative disorders into view, which are often driven by EBV. The group of EBV-associated lymphoproliferative disorders includes different entities, with distinct biological features, ranging from indolent disorders, which may even spontaneously regress, to aggressive lymphomas requiring prompt and adequate treatment. These disorders are often diagnostically challenging due to their overlapping morphology and immunophenotype. Both nodal and extra-nodal sites, including the gastrointestinal tract, may be involved. This review, divided in three parts, summarizes the clinical, pathological, molecular features and treatment strategies of EBV-related lymphoproliferative disorders occurring in the gastrointestinal tract and critically analyzes the major issues in the differential diagnosis. In this part of the review, we discuss plasmablastic lymphoma, extra-cavitary primary effusion lymphoma and Burkitt lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach.
- Author
-
Zanelli, Magda, Pizzi, Marco, Sanguedolce, Francesca, Zizzo, Maurizio, Palicelli, Andrea, Soriano, Alessandra, Bisagni, Alessandra, Martino, Giovanni, Caprera, Cecilia, Moretti, Marina, Masia, Francesco, De Marco, Loredana, Froio, Elisabetta, Foroni, Moira, Bernardelli, Giuditta, Alvarez de Celis, Maria Isabel, Giunta, Alessandro, Merli, Francesco, and Ascani, Stefano
- Subjects
GASTROINTESTINAL diseases ,MAST cell disease ,DIGESTIVE system endoscopic surgery ,HYDROLASES ,HEALTH care teams ,GASTROENTEROLOGISTS ,ONCOLOGISTS - Abstract
Simple Summary: Mastocytosis is a group of neoplastic mast cell disorders ranging from a skin-limited disease to a systemic form with multi-organ involvement, including gut involvement. Clinical manifestations and outcome of systemic mastocytosis are variable. Symptoms may result from either release of mast cell mediators or tissue infiltration by mast cell proliferation. Gastrointestinal symptoms are one of the major causes of morbidity in these patients. The diagnosis of gastrointestinal mastocytosis can be tricky, as symptoms often mimic other more common gastrointestinal diseases; the endoscopic appearance is often unremarkable or nonspecific and the infiltrate can be focal and subtle and easily missed unless special stains are used. This review aims to better define the gastrointestinal involvement in systemic mastocytosis, discussing potential diagnostic pitfalls and pointing out the importance of a multidisciplinary approach for a prompt diagnosis and treatment. Mastocytosis represents a heterogeneous group of neoplastic mast cell disorders. The basic classification into a skin-limited disease and a systemic form with multi-organ involvement remains valid. Systemic mastocytosis is a disease often hard to diagnose, characterized by different symptoms originating from either the release of mast cell mediators or organ damage due to mast cell infiltration. Gastrointestinal symptoms represent one of the major causes of morbidity, being present in 60–80% of patients. A high index of suspicion by clinicians and pathologists is required to reach the diagnosis. Gastrointestinal mastocytosis can be a challenging diagnosis, as symptoms simulate other more common gastrointestinal diseases. The endoscopic appearance is generally unremarkable or nonspecific and gastrointestinal mast cell infiltration can be focal and subtle, requiring an adequate sampling with multiple biopsies by the endoscopists. Special stains, such as CD117, tryptase, and CD25, should be performed in order not to miss the gastrointestinal mast cell infiltrate. A proper patient's workup requires a multidisciplinary approach including gastroenterologists, endoscopists, hematologists, oncologists, and pathologists. The aim of this review is to analyze the clinicopathological features of gastrointestinal involvement in systemic mastocytosis, focusing on the relevance of a multidisciplinary approach. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker.
- Author
-
Zanelli, Magda, Loscocco, Giuseppe G., Sabattini, Elena, Zizzo, Maurizio, Sanguedolce, Francesca, Panico, Luigi, Fanni, Daniela, Santi, Raffaella, Caprera, Cecilia, Rossi, Cristiana, Soriano, Alessandra, Cavazza, Alberto, Giunta, Alessandro, Mecucci, Cristina, Vannucchi, Alessandro M., Pileri, Stefano A., and Ascani, Stefano
- Subjects
STAINS & staining (Microscopy) ,IMMUNOHISTOCHEMISTRY ,MYELOID leukemia ,RETROSPECTIVE studies ,EOSINOPHILIA ,GENE expression ,LYMPHOCYTIC leukemia ,CELL proliferation ,DESCRIPTIVE statistics ,TUMOR markers ,T-cell lymphoma - Abstract
Simple Summary: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia. Given important therapeutic implications, it is crucial to identify T-LBL arising in this particular context. LIM domain only 2 (LMO2) is known to be overexpressed in almost all sporadic T-LBL and not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations. We retrospectively evaluated the clinical, morphological, immunohistochemical and molecular features of 11 cases of T-LBL occurring in the setting of myeloid/lymphoid neoplasms with eosinophilia and investigated the immunohistochemical expression of LMO2 in this setting of T-LBL. Interestingly, 9/11 cases were LMO2 negative, with only 2 cases showing partial expression. In our study, we would suggest that LMO2 immunostaining, as part of the diagnostic panel for T-LBL, may represent a useful marker to identify T-LBL developing in the context of myeloid/lymphoid neoplasms with eosinophilia. Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). Methods and Results: We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively. Conclusions: LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review.
- Author
-
Sanguedolce, Francesca, Zanelli, Magda, Zizzo, Maurizio, Luminari, Stefano, Martino, Giovanni, Soriano, Alessandra, Ricci, Linda, Caprera, Cecilia, and Ascani, Stefano
- Subjects
SYSTEMATIC reviews ,GASTROINTESTINAL tumors ,LYMPHOPROLIFERATIVE disorders ,TUMOR markers ,T-cell lymphoma - Abstract
Simple Summary: This review aims to better define the clinical, pathological, and molecular features of the novel lymphoproliferative disease termed "indolent T-cell lymphoproliferative disorder of the gastro-intestinal tract (iTLPD-GI)", to discuss potential pitfalls in differentiating this entity from other neoplastic and non-neoplastic disorders arising at the same site, and to point out a biomarker-based approach to the diagnosis. iTLPD-GI is a low-grade clonal T-cell lymphoproliferative disease arising in GI organs. It is an uncommon disease, and only recently has it been enlisted as a distinct provisional entity in the current WHO Classification. Data from the literature disclose high heterogeneity in terms of pathological and molecular features; on the other hand, establishing an accurate diagnosis of iTLPD-GI is of pivotal importance, since treatment options are different from that of other, more frequent lymphomas that arise in the gastrointestinal tract. In this review, we aimed to better define this novel entity, and to identify useful diagnostic biomarkers; moreover, we provide a biomarker-based approach to the diagnosis and describe the most common issues in differentiating iTLPD-GI from other neoplastic and non-neoplastic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Familial Mediterranean Fever: Genetic Update.
- Author
-
Soriano, Alessandra and Pras, Elon
- Published
- 2014
48. Primary Pulmonary B-Cell Lymphoma: A Review and Update.
- Author
-
Sanguedolce, Francesca, Zanelli, Magda, Zizzo, Maurizio, Bisagni, Alessandra, Soriano, Alessandra, Cocco, Giorgia, Palicelli, Andrea, Santandrea, Giacomo, Caprera, Cecilia, Corsi, Matteo, Cerrone, Giulia, Sciaccotta, Raffaele, Martino, Giovanni, Ricci, Linda, Sollitto, Francesco, Loizzi, Domenico, Ascani, Stefano, Peperzak, Victor, and Lopera, Marta Cuenca
- Subjects
TREATMENT of lung tumors ,B cell lymphoma ,HEALTH care teams ,LUNG tumors ,SYMPTOMS - Abstract
Simple Summary: The group of B-cell lymphomas primarily involving the lung encompasses different histological entities with distinct biological aspects, while sharing some clinical and radiological features related to their common anatomic site of occurrence. Recent molecular advances in the molecular genetics of these lesions have substantially improved of our understanding of the mechanisms of lymphomagenesis, adding novel information to histology in order to better characterize and manage these diseases. This review summarizes the available clinical, radiological, pathological, and molecular data on primary pulmonary B-cell lymphomas, discusses the mechanisms of lymphomagenesis, and highlights the role of a multi-disciplinary management in overcoming the diagnostic and therapeutic challenges in this setting. Primary pulmonary B-cell lymphomas (PP-BCLs) comprise a group of extranodal non-Hodgkin lymphomas of B-cell origin, which primarily affect the lung without evidence of extrapulmonary disease at the time of diagnosis and up to 3 months afterwards. Primary lymphoid proliferations of the lung are most often of B-cell lineage, and include three major entities with different clinical, morphological, and molecular features: primary pulmonary marginal zone lymphoma of mucosa-associated lymphoid tissue (PP-MZL, or MALT lymphoma), primary pulmonary diffuse large B cell lymphoma (PP-DLBCL), and lymphomatoid granulomatosis (LYG). Less common entities include primary effusion B-cell lymphoma (PEL) and intravascular large B cell lymphoma (IVLBCL). A proper workup requires a multidisciplinary approach, including radiologists, pneumologists, thoracic surgeons, pathologists, hemato-oncologists, and radiation oncologists, in order to achieve a correct diagnosis and risk assessment. Aim of this review is to analyze and outline the clinical and pathological features of the most frequent PP-BCLs, and to critically analyze the major issues in their diagnosis and management. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Erratum to: Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases.
- Author
-
Cimino, Luca, Aldigeri, Raffaella, Marchi, Sylvia, Mastrofilippo, Valentina, Viscogliosi, Fabiana, Coassin, Marco, Soldani, Annamaria, Savoldi, Luisa, De Fanti, Alessandro, Belloni, Lucia, Zerbini, Alessandro, Parmeggiani, Maria, Chersich, Matthew, Soriano, Alessandra, Salvarani, Carlo, and Fontana, Luigi
- Published
- 2018
- Full Text
- View/download PDF
50. Immune Mediated Myopathy following Long-Term Statin Therapy.
- Author
-
Watad, Abdulla, Soriano, Alessandra, Vaknine, Hananya, Shoenfeld, Yehuda, and Amital, Howard
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.